Mini Review
Volume 8 Issue 8 - 2021
Cellular Pathology of COVID on the Heart: A Mini-Review
Sheila Fatehpur1, Johann Philipp Addicks2, Josefina Kusnirova1, Pouria Sabetian3, Muhammad Akram4 and Mirzaie Masoud1*
1Department of Vascular Surgery, OWL, Klinikum Lippe University Hospital, Campus Lemgo, Germany
2Institute of Neuroradiology, OWL, Klinikum Lippe University Hospital, Campus Lemgo, Germany
3Department of Vascular Surgery, Klinikum Mönchengladbach, Germany
4Department of Eastern, Medicine Government College University Faisalabad, Pakistan
*Corresponding Author: Mirzaie Masoud, Professor, Head of the Department of Vascular Surgery OWL, Klinikum Lippe, Campus Lemgo, Germany.
Received: June 11, 2021; Published: July 23, 2021


The course of COVID infections is mainly determined by cardiovascular functional impairment. Patients with preexisting cardiac disease have a significantly worse prognosis than patients with no known cardiac disease. The same applies to comorbidities such as diabetes mellitus and more advanced age. Cardiac involvement can be direct or indirect. Mild and fulminant myocarditis, myocardial scarring, post-infectious arrhythmias and stress cardiomyopathy, among others, can determine the prognosis of patients. ACE-II receptors play a major role in the initiation of endothelititis. Other receptors such as a disintegrin and metalloprotease-17 (ADAM- 17), transmembrane protease serine type2 (TMPRSS2) and neuropilin 1 are also involved in this process. This review provides an overview of the cellular pathology of cardiac impairment in COVID infection.

Keywords: COVID; Heart Failure


  1. Shi S., et al. “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China”. JAMA Cardiology7 (2020): 802-810.
  2. Guo T., et al. “Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)”. JAMA Cardiology7 (20207): 811-818.
  3. Chen, L., et al. “The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2”. Cardiovasc Research6 (2020): 1097-1100.
  4. Shi S., et al. “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China”. JAMA Cardiology7 (2020): 802-810.
  5. Xu Z., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. The Lancet Respiratory Medicine4 (2020): 420-422.
  6. Carvalho-Schneider C Laurent, E., et al. “Follow-up of adults with noncritical COVID-19 two months after symptom onset”. Clinical Microbiology and Infection2 (2021): 258-263.
  7. Huang C., et al. “6-month consequences of COVID-19 in patients discharged from hospital: a cohort study”. Lancet10270 (2021): 220-232.
  8. Jabri A., et al. “Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic”. JAMA Network Open7 (2020): e2014780.
  9. Wu Q., et al. “Altered lipid metabolism in recovered SARS patients twelve years after infection”. Scientific Reports1 (2017): 9110.
  10. Liu PP., et al. “The science underlying COVID-19: implications for the cardiovascular system”. Circulation 142 (2020): 68-78.
  11. Lazzerini PE., et al. “Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies”. Nature Reviews Immunology1 (2019): 63-64.
  12. Agarwal AK., et al. “Postural orthostatic tachycardia syndrome”. Postgraduate Medical Journal981 (2007): 478-480.
  13. Bogoch II., et al. “Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel”. Journal of Travel Medicine 27 (2020): taaa008.
  14. Lu H., et al. “Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle”. Journal of Medical Virology4 (2020): 401-402.
  15. Guo YR., et al. “The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status”. Military Medical Research1 (2020): 11.
  16. Desai AD., et al. “Management of arrhythmias associated with COVID-19”. Current Cardiology Reports2 (2021).
  17. Cascella M., et al. “Features, evaluation, and treatment coronavirus (COVID-19), in StatPearls [internet]. Treasure Island: StatPearls (2021).
  18. Li W., et al. “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”. Nature 426 (2003): 450-454.
  19. Groß S., et al. “SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications”. Journal of Molecular and Cellular Cardiolog 144 (2020): 47-53.
  20. Cooke JP. “The endothelium: a new target for therapy”. Vascular Medicine1 (2000): 49-53.
  21. Pons S., et al. “The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection”. Crit Care1 (2020): 353.
  22. Schiffrin EL., et al. “Hypertension and COVID-19”. American Journal of Hypertension5 (2020): 33-373.
  23. Richardson S., et al. “Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area”. The Journal of the American Medical Association20 (2020): 2052-2059.
  24. Dutka M., et al. “Various aspects of inflammation in heart failure”. Heart Failure Reviews 25 (2020): 537-548.
  25. Becker RC. “COVID-19 update: Covid-19-associated coagulopathy”. The Journal of Thrombosis and Thrombolysis1 (2020): 54-67.
  26. Dolhnikoff M., et al. “Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19”. Journal of Thrombosis and Haemostasis6 (2020): 1517-1519.
  27. Danzi GB., et al. “Acute pulmonary embolism and COVID-19 pneumonia: a random association?” European Heart Journal19 (2020): 1858.
  28. Poissy J., et al. “Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence”. Circulation2 (2020): 184-186.
  29. Ullah W., et al. “COVID-19 complicated by acute pulmonary embolism and right-sided heart failure”. JACC: Case Reports9 (2020): 1379-1382.
  30. Schultz NH., et al. “Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination”. The New England Journal of Medicine (2021): NEJMoa2104840.
  31. Greinacher A., et al. “Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination”. The New England Journal of Medicine (2021): NEJMoa2104840.
  32. Cantuti-Castelvetri, L., et al. “Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity”. Science6518 (2020): 856-860.
  33. Daly JL., et al. “Neuropilin-1 is a host factor for SARS-CoV-2 infection”. Science6518 (2020): 861-865.
  34. Li Z and Buck M. “Neuropilin-1 assists SARS-CoV-2 infection by stimulating the separation of spike protein domains S1 and S2”. Bio Rxiv (2021).
  35. Elpek GÖ. “Neuropilins and liver”. World Journal of Gastroenterology23 (2015): 7065-7073.
  36. Roy S., et al. “Multifaceted role of neuropilins in the immune system: potential targets for immunotherapy”. Frontiers in Immunology 8 (2017): 1228.
  37. Nasarre C., et al. “Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo”. Oncogene 16 (2010): 2381-2392.
  38. Moin ASM., et al. “The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome”. Metabolism Open 9 (2021): 100079.
  39. Mayi BS., et al. “The role of Neuropilin-1 in COVID-19”. PLoS Pathology1 (2021): e1009153.
  40. Machhi J., et al. “The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections”. Journal of Neuroimmune Pharmacology3 (2020): 359-386.
  41. Li W., et al. “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”. Nature 426 (2003): 450-454.
  42. Lan J., et al. “Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor”. Nature7807 (2020): 215-220.
  43. Iwata-Yoshikawa N., et al. “TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection”. Journal of Virology6 (2019): e01815-01818.
  44. Li F., et al. “Structure of SARS coronavirus spike receptor-binding domain complexed with receptor”. Science 309 (2005): 1864-1868.
  45. Kuba K., et al. “Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters”. Pharmacology and Therapeutics1 (2010): 119-128.
  46. Crackower MA., et al. “Angiotensin-converting enzyme 2 is an essential regulator of heart function”. Nature 417 (2002): 822-828.
  47. Lambert DW., et al. “Tumor Necrosis Factor-α Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2)”. Journal of Biological Chemistry 280 (2005): 30113-30119.
  48. Epelman S., et al. “Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure”. Journal of the American College of Cardiology 52 (2008): 750-754.
  49. Sama IE., et al. “Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors”. European Heart Journal 41 (2020): 1810-1817.
  50. Oudit GY and Pfeffer MA. “Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19”. European Heart Journal 41 (2020): 1818-1820.
  51. Satoh M., et al. “Expression of tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human myocarditis”. Journal of the American College of Cardiology 36 (2000): 1288-1294.
  52. Satoh M., et al. “Increased expression of tumor necrosis factor-α converting enzyme and tumor necrosis factor-α in peripheral blood mononuclear cells in patients with advanced congestive heart failure”. European Journal of Heart Failure 6 (2004): 869-875.
  53. Chen C., et al. “Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19”. Zhonghua Xin Xue Guan Bing Za Zhi7 (2020): 567-571.
  54. Bonow RO., et al. “Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality”. JAMA Cardiology7 (2020): 751-753.
  55. Xiong TY., et al. “Coronaviruses and the cardiovascular system: acute and long-term implications”. European Heart Journal19 (2020): 1798-1800.
  56. Colafrancesco S., et al. “COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome?” Autoimmunity Reviews7 (2020): 102573.
  57. Ruan Q., et al. “Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China”. Intensive Care Medicine 46 (2020): 846-848.
  58. Wu C., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China”. JAMA Internal Medicine7 (2020): 934-943.
  59. Behrens EM and Koretzky GA. “Review: cytokine storm syndrome: looking toward the precision medicine era”. Arthritis and Rheumatology6 (2017): 1135-1143.
  60. Azkur AK., et al. “Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19”. Allergy7 (2020): 1564-1581.
  61. Zheng YY., et al. “COVID-19 and the cardiovascular system”. Nature Reviews Cardiology5 (2020): 259-260.
  62. Alexander LK., et al. “An experimental model for dilated cardiomyopathy after rabbit coronavirus infection”. The Journal of Infectious Diseases5 (1992): 978-985.
  63. Small JD., et al. “Rabbit cardiomyopathy associated with a virus antigenically related to human coronavirus strain 229E”. The American Journal of Pathology 95 (1979): 709-729.
  64. Sama IE., et al. “Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors”. European Heart Journal19 (2020): 1810-1817.
  65. Ingraham NE., et al. “Understanding the renin-angiotensin-aldosterone-SARS-CoV-Axis: a comprehensive review”. European Heart Journal1 (2020): 2000912.
  66. Palau V., et al. “ADAM17 inhibition may exert a protective effect on COVID-19”. Nephrology Dialysis Transplantation6 (2020): 1071-1072.
  67. Ren J., et al. “Estrogen upregulates MICA/B expression in human nonsmall cell lung cancer through the regulation of ADAM17”. Cellular and Molecular Immunology6 (2015): 768-776.
  68. Rizzo P., et al. “COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?” Basic Research in Cardiology3 (2020): 31.
  69. Zidar DA., et al. “Association of lymphopenia with risk of mortality among adults in the US general population”. JAMA Network Open12 (2019): e1916526.
  70. Saltiel AR and Olefsky JM. “Inflammatory mechanisms linking obesity and metabolic disease”. Journal of Clinical Investigation1 (2017): 1-4.
  71. Driggin E., et al. “Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic”. Journal of the American College of Cardiology18 (2020): 2352-2371.
  72. Zhang L., et al. “Bedside Focused Cardiac Ultrasound in COVID-19 from the Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care Echocardiography”. Journal Info. American Society of Echocardiography6 (2020): 676-682.
  73. Choi Y., et al. “Risk evaluation of azithromycin-induced QT prolongation in real-world practice”. BioMed Research International (2018): 1574806.
  74. Sears SP., et al. “Incidence of sustained ventricular tachycardia in patients with prolonged QTc after the administration of azithromycin: a retrospective study”. Drugs Real World Outcome1 (2016): 99-105.
  75. Huang BH., et al. “Azithromycin-induced torsade de pointes”. Pacing and Clinical Electrophysiology12 (2007): 1579-1582.
  76. Kezerashvili A., et al. “Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors”. The Journal of Interventional Cardiac Electrophysiology3 (2007): 243-246.
  77. Ray WA., et al. “Azithromycin and the risk of cardiovascular death”. The New England Journal of Medicine20 (2012): 1881-1890.
  78. Zhang M., et al. “Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin”. Cardiovascular Toxicology4 (2017): 434-440.
  79. Capel RA., et al. “Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: novel electrophysiological insights and therapeutic potential”. Heart Rhythm10 (2015): 2186-2194.
  80. Malviya A. “Ventricular arrhythmia risk due to chloroquine/hydroxychloroquine treatment for COVID-19: Should it be given”. Indian Heart Journal2 (2020): 131-132.
Citation: Mirzaie Masoud., et al. “Cellular Pathology of COVID on the Heart: A Mini-Review”. EC Cardiology 8.8 (2021): 03-10.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

September Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the September issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before September 28, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to